The brand of pharmaceutical firm Novo Nordisk is displayed in entrance of its places of work in Bagsvaerd, on the outskirts of Copenhagen, Nov. 24, 2025.
Tom Little | Reuters
Novo Nordisk will begin rolling out the first-ever GLP-1 tablet for weight reduction within the U.S. on Monday, the corporate introduced, marking a new chapter of weight problems therapy within the U.S.
The drug’s money costs are among the many lowest in the marketplace, starting from $149 to $299 per thirty days, relying on the dose. That fuels hopes that tablets may assist handle the long-standing affordability hurdles tied to the weekly injections dominating the load loss drug market.
The official launch of the oral drug, referred to as the Wegovy tablet, comes simply two weeks after U.S. regulators cleared the therapy.
The beginning dose of 1.5 milligrams is on the market at greater than 70,000 U.S. pharmacies comparable to CVS and Costco, in addition to choose telehealth suppliers, together with Ro, LifeMD, Weight Watchers, GoodRx and Novo Nordisk’s NovoCare Pharmacy. The upper, remaining doses of the tablet will likely be accessible to sufferers by the tip of the week, Novo Nordisk stated.
Money-paying sufferers pays $149 per thirty days for the beginning dose. The 4-milligram dose of the tablet will even be accessible for $149 per thirty days via April 15, then $199 per thirty days after that.
The best doses of the Wegovy tablet – 9 milligrams and 25 milligrams – will likely be accessible for $299 per thirty days. Sufferers with insurance coverage protection for the drug pays as little as $25 per thirty days for the therapy.
Money-paying sufferers will even be capable of entry the beginning dose of the tablet for $149 per thirty days on President Donald Trump‘s direct-to-consumer web site, TrumpRx, beneath a deal Novo Nordisk struck together with his administration in November. The location additionally launches in January, although it is unclear when.
Novo Nordisk on Monday stated the tablet’s availability “opens new prospects” for the greater than 100 million Individuals dwelling with weight problems.
Injections from Novo Nordisk and its chief rival, Eli Lilly, carry a listing worth of roughly $1,000 per thirty days. However each firms supply decrease cash-pay costs for his or her photographs that vary from $299 to $499 month-to-month, relying on the dose.
Capsules are the subsequent battleground for the 2 firms, which established the booming GLP-1 house that some analysts say may very well be price roughly $100 billion by the 2030s. Goldman Sachs analysts stated in August that oral medicine may seize a 24% share — or round $22 billion — of the 2030 world weight reduction drug market.
The launch of Novo Nordisk’s every day oral drug on Monday offers the corporate a transparent head begin. The Meals and Drug Administration permitted the therapy on Dec. 22 and can resolve whether or not to clear a rival tablet from Eli Lilly later this yr.
The FDA additionally permitted Novo Nordisk’s tablet to be used to cut back the chance of main cardiovascular occasions, comparable to loss of life, coronary heart assault or stroke, in adults with weight problems and established heart problems.
That is in line with the approval label of the corporate’s blockbuster weight reduction drug Wegovy, which shares the identical energetic ingredient, semaglutide. Each work by mimicking the intestine hormone GLP-1 to suppress urge for food.
“This second is about altering what’s potential in weight administration, and to make that potential, we’ve labored to make sure [the Wegovy pill] is inexpensive and accessible to those that want it, nevertheless they select to obtain their care,” stated Ed Cinca, Novo Nordisk’s senior vice chairman of promoting and affected person options, in a launch.
Individuals who take Novo Nordisk’s tablet have to attend half-hour earlier than consuming or consuming every day.
In a section three trial that adopted greater than 300 adults with weight problems and never diabetes, the best dose of Novo Nordisk’s oral semaglutide helped sufferers lose as much as 16.6% of their weight on common after 64 weeks. That weight reduction was 13.6% when the corporate analyzed all sufferers no matter whether or not they stopped the drug.
The tablet seems to be barely simpler than Eli Lilly’s experimental oral drug, which doesn’t have dietary restrictions.
